No Data
Shenzhen YHLO Biotech Co., Ltd. (SHSE:688575) Insiders, Who Hold 48% of the Firm Would Be Disappointed by the Recent Pullback
Yahui Long (688575.SH): The heparin-binding protein testing kit has obtained the medical instruments registration certificate.
Gelonghui, on March 24, reported that Yahuilong (688575.SH) announced that it has recently received a medical instruments registration certificate issued by the Guangdong Provincial Pharmaceutical Supervision Administration, for the product name: Heparin Binding Protein Assay Kit (Chemiluminescence Method). As of now, the company has obtained a total of 171 domestic "Medical Instruments Registration Certificates" for chemiluminescence reagents (a total of 244 domestic registration certificates for luminescent reagents). The acquisition of this "Medical Instruments Registration Certificate" is beneficial for further enriching the company’s fully automated chemiluminescence product line, expanding Yahuilong's testing packages in the inflammation field, and enhancing the comprehensive competitiveness of the company's products.
Shenzhen YHLO Biotech Gets China Copyright Nod for Diabetes Diagnosis Software
Yahui Long (688575.SH) has obtained two software copyrights: the standardized pancreatic function assessment system assists in precise diabetes diagnosis and treatment.
On March 16, Gelonghui reported that Yahui Long (688575.SH) announced that the company recently obtained two Computer software copyright registration certificates issued by the National Copyright Administration. The software names are: Insulin Function Standardization Evaluation System (Web version) [abbreviated as: multipif-web] V1.0; and Insulin Function Standardization Evaluation Mini Program [abbreviated as: multipif-mp] V1.0. The Insulin Function Standardization Evaluation System Software is a smart platform jointly developed by Yahui Long, Jiangsu Provincial People's Hospital, and Nanjing Medical University.
Yahui Long (688575.SH): Termination of the implementation of the 2024 restricted Stocks incentive plan.
On March 14, Gelonghui reported that Yahui Long (688575.SH) held the third meeting of the fourth Board of Directors and the third meeting of the fourth Supervisory Board on March 13, 2025, reviewing and approving the proposal to terminate the implementation of the 2024 Restricted Stocks Incentive Plan. This termination is the result of the company’s repeated demonstrations and careful research, reflecting the company's high attention to market changes and timely adjustment of its Global Strategy. After the termination of this incentive plan, the company will continue to act responsibly towards all Shareholders, continuously empowering organizational structure, optimizing the existing compensation system, and improving.
Yahui Long (688575.SH): reaccredited as a high-tech enterprise.
On March 11, Glorious Exchange announced that Yahui Long (688575.SH) has recently received the "High-tech Enterprise Certificate" jointly issued by the Shenzhen Municipal Bureau of Industry and Information Technology, the Shenzhen Municipal Finance Bureau, and the State Taxation Administration of Shenzhen. The certificate number is: GR202444202012, issued on December 26, 2024, with a validity period of three years. This recognition is a re-evaluation conducted after the expiration of the company's original high-tech enterprise certificate.
Shenzhen YHLO Biotech Co., Ltd.'s (SHSE:688575) Popularity With Investors Is Under Threat From Overpricing
